News
Standard & Poor's Initiates Factual Stock Report Coverage on Mymetics Corporation
NEW YORK-(Business Wire)-October 2, 2008 - Standard & Poor’s announced today that it has commenced Factual Stock Report coverage on Mymetics Corporation.
Mymetics Corporation (OTCBB:MYMX), is a biotechnology company focused on developing prophylactic vaccines, presently focusing on vaccines against the human immunodeficiency virus (HIV/AIDS) and malaria.
The company's vaccines combine advanced antigen engineering, minimal human protein homologies, and virosome technology as an efficient carrier with broad adjuvant characteristics and high safety profile, widely approved and commercialized since 1994. Mymetics seeks to develop vaccines that protect by preventing early transmission from taking place within the first hours following exposure, such as the mucosal entry of pathogens, as well as to protect against later events.
Mymetics intends to grow its pipeline of vaccines through acquisitions and integration of these acquisitions into the company's existing product pipeline. It plans to initiate Phase I trials for its HIV/AIDS preventive vaccine in Q4 2008. The company's malaria vaccine has completed Phase I and II trials in Europe and is completing Phase Ib in Tanzania with children and teenagers under native endemic conditions.
The company has established a substantial outsource network which enables it to work with academic research centers, pharmaceutical laboratories, biotechnology companies and other best-in-class partners.
This report will also be accessible on an ongoing basis to the investment community —— scores of buy-side institutions and sell-side firms that utilize S&P research and information platforms daily. Millions of self-directed investors also have access to the report via their e-brokerage accounts.
About Standard & Poor's Factual Stock Reports
This Standard & Poor’s service provides factual research coverage enabling information about Mymetics Corporation and other securities to reach a wide investor audience of Buy and Sell-side investors, helping them understand a company’s fundamentals and business prospects. Currently profiling over 1,000 issuers, S&P Factual Stock Reports increase market awareness for issuers in the investment community with insightful commentary and key statistics/information. Updated weekly with the latest pricing, trading volume, and other data, the reports include recent developments, a financial review, key operating information, Industry and peer comparisons, institutional holdings analysis, Street Consensus and opinions, performance charts, business summary, fundamental data, and news. Because coverage of these reports is sponsored by the issuer, S&P does not offer investment opinions concerning the advisability of investing in these stocks.
Standard & Poor’s Factual Stock Reports are produced separately from any other analytic activity of Standard & Poor’s. Standard & Poor’s Factual Report research has no access to non-public information received by other units of Standard & Poor’s. Standard & Poor’s does not trade on its own account.
Note: All U.S. and Canadian Companies listed on a National Exchange (not covered by S&P’s STARS research) are eligible to obtain this coverage.
About Standard & Poor's
Standard & Poor's, a division of The McGraw-Hill Companies (NYSE: MHP), is the world's foremost provider of financial market intelligence, including independent credit ratings, indices, risk evaluation, investment research and data. With approximately 8,500 employees, including wholly owned affiliates, located in 23 countries, Standard & Poor's is an essential part of the world's financial infrastructure and has played a leading role for more than 140 years in providing investors with the independent benchmarks they need to feel more confident about their investment and financial decisions. For more information, visit http://www.standardandpoors.com.
 |
 |
 |
|
||
 |
|
 |
|
||
Search Our News Using Google Search
Can't find what you want? Try using Google:
